RxDoctor Payments Data

Veronica Spandler

Physician Assistant · San Francisco, CANPI 1023626314

Payments from drug & device makers

$1,603in general payments, 2019–2025

Across 69 payments — averaging $23.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$443
  • AstraZeneca$212
  • Takeda Pharmaceuticals U.S.A., Inc.$146
  • Daiichi Sankyo Inc.$129
  • Gilead$125
  • Merck$102
  • plus $447 from 11 others

What the payments were for

  • Food & beverage$1,40488%
  • Education$19912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,603 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$105,677
Medicare patients
142
Services billed
1,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate15$235,031
CalquenceAcalabrutinib Maleate12$186,223
CreonLipase/Protease/Amylase11$18,774
Imatinib Mesylate14$14,765
Anastrozole28$685
Ondansetron Hcl20$509
Acyclovir20$380
Prochlorperazine Maleate16$261
Mirtazapine14$193
Potassium Chloride21$190
Pantoprazole Sodium24$157
Omeprazole13$96
Allopurinol14$78
Lorazepam12$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$443$235,03115 claims
AstraZenecaCalquence$212$186,22312 claims
AbbVieCreon$53$18,77411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →